Categories: Health

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

 | Source: Taysha Gene Therapies, Inc.

DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha’s Board of Directors granted one new employee an option to purchase 90,000 shares of the Company’s common stock in connection with their employment. The stock option was granted under the Taysha Gene Therapies, Inc. 2023 Inducement Plan as an inducement material to the individual entering employment with Taysha in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.63 which is equal to the closing price of Taysha’s common stock on the date of grant. The stock option has a 10-year term and will vest over four years, with 25% of the option vesting on the first anniversary of the vesting commencement date and the remaining 75% of the option vesting in equal monthly installments over the 36 months thereafter. Vesting of the stock option is subject to such employee’s continued service to Taysha on each vesting date.

About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system. Its lead clinical program TSHA-102 is in development for Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. With a singular focus on developing transformative medicines, Taysha aims to address severe unmet medical needs and dramatically improve the lives of patients and their caregivers. The Company’s management team has proven experience in gene therapy development and commercialization. Taysha leverages this experience, its manufacturing process and a clinically and commercially proven AAV9 capsid in an effort to rapidly translate treatments from bench to bedside. For more information, please visit http://www.tayshagtx.com.

Company Contact:
Hayleigh Collins
Senior Director, Corporate Communications and Investor Relations
Taysha Gene Therapies, Inc.
hcollins@tayshagtx.com

Media Contact:
Carolyn Hawley
Inizio Evoke
Carolyn.hawley@inizioevoke.com

GlobeNews Wire

Recent Posts

RCKT Deadline: Rosen Law Firm Urges Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) Stockholders with Losses in Excess of $100K to Contact the Firm for Information About Their Rights

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a…

59 minutes ago

CORRECTING and REPLACING Berkshire Hathaway Inc. News Release

OMAHA, Neb.--(BUSINESS WIRE)--First paragraph under second table, second sentence should read: At June 30, 2025,…

59 minutes ago

Shell completes sale of interest in Colonial Enterprises Inc. to Brookfield subsidiary

HOUSTON, July 31, 2025 /PRNewswire/ -- Shell Midstream Operating LLC (SMUS), a subsidiary of Shell…

1 hour ago

IBM Report: 13% Of Organizations Reported Breaches Of AI Models Or Applications, 97% Of Which Reported Lacking Proper AI Access Controls

U.S. breach costs rise to $10.22 million, despite the global average cost of a breach…

1 hour ago

Financire de Tubize – 2025 half-year financial report

August 02, 2025 02:00 ET  | Source: Financière de Tubize SA Half-year financial report 2025Regulated…

10 hours ago

Kia Announces July 2025 Global Sales Results

July 2025 global sales of 262,705 units, up 0.3% Y/yOutside of Korea, Kia sold 217,188…

10 hours ago